• Registry-based studies indicate a link between arterial-and venous thromboembolism (VTE)
Results from prospective cohorts, applying cause-specific regression models, have revealed that among the traditional atherosclerotic risk factors, only age, obesity and familial predisposition for MI are shared risk factors for ATD and VTE [6] [7] [8] [9] . In a case-control study, patients with unprovoked VTE were reported to have a higher frequency of carotid plaques than control participants [2] . Conversely, subsequent large population-based cohort studies have failed to confirm an association between carotid atherosclerosis and VTE [10] [11] [12] , indicating that atherosclerosis is not a shared risk factor for ATD and VTE.
Population-based registry studies have shown that patients with a history of MI are at increased short-term risk of subsequent VTE [13, 14] . However, results from registry-based linkage studies should be interpreted with caution as they often lack information about confounders and have limited validation of exposure and outcomes. For instance, an evaluation of the Danish National Patient Registry revealed that the positive predictive values (PPV) for VTE diagnoses from emergency departments and hospitals were only 44% and 67-77%, respectively [15] . Moreover, lack of important clinical information, such as body mass index (BMI), has limited the ability to adjust for confounding in previous registry-based studies [13, 14] .
We therefore aimed to investigate the association between MI and future risk of VTE in a population-based cohort with validated information on exposure (MI), endpoint (VTE), and potential confounders.
Materials and Methods

Study Population
The Tromsø Study is a single-center, prospective, population-based study, with repeated health surveys of the inhabitants of Tromsø, Norway. Study participants were recruited from the fourth, fifth and sixth survey of the Tromsø Study, conducted in 1994-95, 2001-02 and 2007-08, respectively. The overall attendance rates were high; 77% in the fourth, 78% in the fifth and 66% in the sixth survey. A detailed description of the Tromsø study has been published elsewhere [16] . In total, 30 586 unique participants aged 25 to 97 years participated in at least one of the surveys, and of these, 21 529 participants participated in two or all three surveys. Participants who did not consent to medical research (n=225), participants not officially registered as inhabitants of the municipality of Tromsø at the date of study enrollment (n=48), and participants with a previous history of VTE (n=78) or MI (n=729) before baseline were excluded.
Consequently, 29 506 participants were included in the study, and followed from the date of enrollment to the end of follow up, 31 st of December 2010 (Fig. 1) . The regional committee for medical and health research ethics in North Norway approved the study, and all participants gave their informed written consent.
Baseline measurements 
Registry of VTE
All incident VTE events during follow-up were identified by searching the hospital discharge diagnosis registry, the autopsy registry and the radiology procedure registry at the University Hospital of North Norway as previously described [19] . The University Hospital of North Norway is the only hospital in the region, and all diagnostic radiology and hospital care is provided exclusively by this hospital. The medical record for each potential case of VTE was reviewed by trained personnel, and a VTE event was considered verified and recorded when presence of clinical signs and symptoms of DVT or PE were combined with objective confirmatory tests (i.e.
compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation scan, pulmonary angiography or autopsy), and resulted in a VTE diagnosis that required treatment, as previously described in detail [19] . VTE cases from the autopsy registry were recorded when the death certificate indicated VTE as cause of death or a significant condition associated with death. The VTE events were classified as provoked or unprovoked depending on the presence of provoking factors at the time of diagnosis. Provoking factors included recent surgery or trauma within the previous 8 weeks, acute medical conditions (i.e. acute MI, ischemic stroke or major infectious diseases), active cancer, immobilization (i.e. bed rest >3 days, wheelchair use or long-distance travel exceeding 4 hours within the last 14 days prior to the event), or any other factor described by a physician in the medical record (e.g. intravascular catheter).
Statistical Analysis
Participants who developed MI during the study period contributed with non-exposed persontime from the inclusion date to the date of a diagnosis of MI, and then with exposed person-time from the date of MI onwards. For each participant, non-exposed and exposed person-years were counted from the date of enrollment to the date of an incident diagnosis of VTE, the date the participant died or moved from Tromsø, or until the end of the study period, 31 st of December 2010, whichever came first. Participants who died or moved from the municipality during followup were censored at the date of death or migration.
Statistical analyses were performed using STATA version 14.0 (Stata Corporation, College Station, TX, USA). Crude incidence rates (IR) of VTE were calculated and expressed as number of events per 1 000 person-years at risk. Cox proportional hazards regression models were used to calculate hazard ratios (HR) with 95% confidence intervals (CI) of VTE, DVT and PE after MI. Age was used as time scale in the Cox model, with the age of the participants at study enrollment defined as entry time and age at the VTE event or censoring event (i.e. death, migration, or the date of study end) defined as exit time. MI was included as a time-dependent covariate in the Cox model. Therefore, participants who developed MI during follow-up contributed with person-years in both the unexposed and exposed group. In those who participated in several surveys, information on possible potential confounders was updated at each survey. We estimated HRs with three different models. The first model was adjusted for age (as time scale) and sex, while the second model was additionally adjusted for BMI. Model 3 was adjusted for age (as time scale), sex, BMI, diabetes mellitus, smoking, systolic blood pressure, HDL-cholesterol, physical activity and education.
The proportional hazard assumption was tested using Schoenfeld residuals and found not violated. Statistical interactions between MI and sex were tested by including cross-product terms in the proportional hazards models, and no interactions was found.
Attributable risk (AR), the proportion of events among the exposed participants that could be explained by the exposure, was calculated from incidence rates of VTE in the MI (Ie) and non-MI (Io) population and expressed as a percentage (AR=100x(Ie-Io)/Ie)). Population attributable risk (PAR), the proportion of events in the population that could be attributed to the exposure, was calculated based on incidence rates of VTE in the total population (Ip) and in the nonexposed population (Io) and expressed as a percentage (PAR= 100x(Ip-Io)/Ip)). GraphPad Prism 
Results
There were 1 892 (6.4%) participants who developed a first-time MI and 699 (2.4%) participants who developed a first-time VTE during a median 15.7 years of follow-up. Baseline characteristics of the study participants with and without MI are shown in Table 1 . Participants with MI had higher mean age and BMI, and a higher proportion of men, smokers, and participants with hypertension than those without MI (Table 1) .
Characteristics of the VTE events are shown in Incidence rates and hazard ratios of VTE were high immediately after the MI and declined rapidly thereafter (Table 5 and Figure 2 ). The incidence rate of VTE was 18 per 1 000
person-years, and the hazard ratio of VTE was 5-fold higher in participants with compared to those without MI during the first 6 months after the incident MI diagnosis (adjusted HR 4.86; 95% CI, 2.57-9.05). Following the initial 6 months after the MI, the risk of VTE was not significantly increased (Table 5 ). Separate analysis of PE showed a similar, though augmented, risk pattern.
The multivariable HR for PE during the first 6 months after MI was 8.49 (95% CI, 4.00-18.17).
The risk of PE remained almost 4-fold higher from 6 months to 1 year after the MI compared to the risk in those without MI (adjusted HR 3.78; 95% CI, 1.20-11.89), but the association disappeared when the observation period was extended beyond 1 year (Table 5) .
Discussion
In our population-based cohort, participants with MI had higher risk of subsequent VTE, and PE in particular, compared to participants without MI in analyses adjusted for traditional atherosclerotic risk factors. The risk estimates for PE were highest during the first 6 months after the MI and declined rapidly thereafter. We found that 78.5% of the PE events among MI-patients could be attributed to the MI, whereas 6.2% of the PEs in the population could be attributed to MI.
Previous studies have indicated an association between MI and increased risk of future VTE. In a meta-analysis of placebo-controlled trials evaluating the effect of antithrombotic drugs, 4% of patients with MI had a symptomatic PE during the first two weeks after the MI event. [20] A relation between MI and PE was further supported in a cross-sectional study where an association between coronary heart disease and PE was found in patients aged 60 years or older. [21] In agreement with our findings, Sørensen and colleagues found that the risk of VTE, and PE in particular, was higher in the first months immediately after a MI when compared with the VTE risk in population-based controls in two registry-based case-control studies [ A direct causal relation between MI and VTE may also contribute to VTE risk in MI patients. Local disturbances in the cardiopulmonary circulation after MI may predispose for thrombus formation by stasis in the pulmonary circulation due to backward failure secondary to left ventricular dysfunction [28, 29] , by injury of the vascular endothelium [30] , or by activation of the coagulation system during the acute phase of MI [31] . Atrial fibrillation is a frequent complication after MI [32] . Recently, we reported that atrial fibrillation was associated with increased risk of VTE, and PE in particular [33] . According to the transient nature of VTE risk and the particularly high risk of PE observed in our study, it is likely to assume that direct causal mechanism(s) secondary to local disturbances in the cardiopulmonary circulation or electromechanical activity (e.g. atrial fibrillation) may convey parts of the VTE risk after MI. Previous studies have shown that DVT can be identified in only 50% of patients with PE, [34] which supports the concept that pulmonary thrombi may form de novo in the lungs or origin from other sources of emboli. Alternatively, the high PE rather than DVT risk after MI may be explained by detection bias since patients with previous MI are more likely to undergo examinations for chest pain.
Our findings may have some clinical implications. In our population-based cohort, 6.2 % of PE events could be attributed to MI exposure, and 78% of the VTE events among the MI patients were attributable to the MI itself. These numbers may actually be an underestimation due to concomitant use of drugs (aspirin, heparins, and statins) in MI, which is known to reduce the VTE risk. The high amount of PE explained by exposure to MI may suggest that anticoagulant treatment of MI patients would prevent several subsequent PE events.
Randomized clinical trials have shown that prolonged oral anticoagulant treatment with vitamin K antagonists (VKA) is equal to (Waris II trial) [35] or superior to (ASPECT II trial) [36] antiplatelet treatment for recurrent MI. Unfortunately, none of these studies have reported VTE as a secondary endpoint. Furthermore, VKA and non-vitamin K oral anticoagulants (NOACs) have been shown to reduce the incidence of recurrent VTE by approximately 90%. However, the impact of anticoagulant treatment together with antiplatelet treatment to prevent PE in MI patients needs to be weighed against the expected bleeding risk of combined treatment [35, [37] [38] [39] . Alternatively, the transient nature of VTE risk after MI, may suggest that MI patients may benefit more from extended thromboprophylaxis with low-molecular weight heparins (LMWH) or
NOACs with an expected efficacy of 50-70% prevention of VTEs over the first 3-6 months [40, 41] .
Major strengths of our study include the prospective design, the large number of participants recruited from a general population, the long-term follow-up, the wide age distribution, the updated confounder information, and the validated events of VTE and MI. As many cardiovascular risk factors are modifiable, some participants' individual risk profile may change during follow-up, leading to regression dilution bias and an underestimation of the associations. However, an advantage in our study is the repeated measurements of subject characteristics during follow-up. Due to this, we may to a greater extent explore the real effect of cardiovascular risk factors on the outcomes during follow-up, resulting in more reliable risk estimates than in a traditional cohort study. Yet, our study has some potential limitations. In a cohort study, non-response bias is a possible limitation. Those who participate in cohort studies tend to be healthier and more interested in their health than the general population. Our estimated incidence may therefore be lower than the true incidence. Further, the low number of both exposure and outcome events in the present cohort may lead to low statistical power to assess the potential impact of MI on the risk of VTE, particularly in subgroup-analyses.
In conclusion, the present cohort study implies that first-lifetime MI is associated with increased risk of VTE, and particularly PE. The transient nature of the VTE risk after MI suggests that direct or indirect causal mechanisms related to the MI event itself are primarily responsible for the observed association. We found that 6.2% of the VTE events in the population could be attributed to MI. *Only women included in the analysis. †Current or previous use of hormone replacement therapy or oral contraceptives. ‡Myocardial infarction in a first-degree relative before 60 years of age. §Bed rest>3 days, journeys of>4 h by car, boat, train or air within the last 14 days, or other types of immobilization.
||Other provoking factor described by a physician in the medical record (e.g. intravascular catheter). 
